Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M

Nuvation Bio Inc.

2024-Q1 EPS reported -$0.07

Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.
Cash, equivalents and marketable securities of $597.0M as of March 31, 2024.
Acquisition of AnHeart Therapeutics closed in April 2024, transforming Nuvation into late-stage global oncology company.
Appointed Colleen Sjogren as Chief Commercial Officer; first patient dosed in Phase 1/2 study of NUV-1511 DDC.
Updated taletrectinib Phase 2 TRUST-I data to be presented at ASCO 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.

Period: the first quarter ended March 31, 2024
Net income: $14.8 million
EPS: $(0.07) per share
Result: reported results

Exact text from the filing

For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-138263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.